Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00190788 · ClinicalTrials.gov registry record · Phase 3
Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion
A Phase 3 study of Sepsis and Hypotension, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
- 2
- Study locations
NCT00190788 is a Phase 3 study of Sepsis and Hypotension that has completed, run by Eli Lilly and Company. The registered enrollment target is 200 participants, below the 6,562-participant average among 90 other Sepsis trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00190788, a Phase 3 study of Sepsis and Hypotension, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine whether continued administration of Drotrecogin Alfa (Activated) up to additional 72 hours - after the so far recommended 96 hour infusion period - results in a more rapid resolution of hypotension in severe septic patients.
Conditions Studied
Interventions
- DRUG placebo
- DRUG Drotrecogin Alfa (Activated)
Study Locations (2)
California
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Loma Linda
Other
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Paris
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2004-06 |
| Est. Completion | 2007-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00190788
The ClinicalTrials.gov registry entry for NCT00190788 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,562-participant average among 90 other Sepsis trials with a reported enrollment target (97% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sepsis appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00190788 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Other.
Frequently Asked Questions
What is clinical trial NCT00190788 about?
NCT00190788 is a clinical study titled "Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion". The purpose of this study is to determine whether continued administration of Drotrecogin Alfa (Activated) up to additional 72 hours - after the so far recommended 96 hour infusion period - results in a more rapid resolution of hypotension in severe septic patients.
What is the current status of trial NCT00190788?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2004-06. Estimated completion is 2007-05.
What conditions does trial NCT00190788 study?
This clinical trial studies the following conditions: Sepsis, Hypotension.
What interventions are being tested in trial NCT00190788?
The interventions under investigation include: placebo (DRUG), Drotrecogin Alfa (Activated) (DRUG).
Who is sponsoring clinical trial NCT00190788?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00190788 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Limited Versus Extended Trophic Feeding (LET-FEED) Trial
RECRUITING · Phase 3
-
A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)
RECRUITING · Phase 3
-
A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer
COMPLETED · Phase 3
-
The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure
COMPLETED · Phase 3
-
Glutamine Supplementation to Prevent Death or Infection in Extremely Premature Infants
COMPLETED · Phase 3
-
The APS Phenotyping Study
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.